EC Approves AbbVie's RINVOQ for Polyarticular Juvenile Idiopathic Arthritis

Key Facts

1The European Commission approved RINVOQ for the treatment of active polyarticular juvenile idiopathic arthritis in patients aged two years and older.

In a move that strengthens the company's position in the biologics sector, AbbVie has received European Commission approval for RINVOQ (upadacitinib) for a new pediatric indication. The approval covers the treatment of active polyarticular juvenile idiopathic arthritis in patients aged two years and older who have shown an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs). The decision was supported by data from the Phase 1 SELECT-YOUTH study and clinical evidence from adult patients.

This expansion into the European market comes as AbbVie continues to bolster its therapeutic portfolio, with ABBV shares closing at $264.48 per market data (close September 21, 2026). The approval is strategically significant given that juvenile idiopathic arthritis impacts approximately 126,000 children in Europe, opening a new growth channel for the company in the autoimmune disease segment.

Regarding stock performance, ABBV reached a day high of $266.6 and a low of $261.23 during its last trading session (close September 21, 2026). With no major upcoming economic calendar events specifically targeting the pharmaceutical sector in the next few days, investors will focus on how this regulatory milestone impacts the company's revenue in the coming quarters.